TY - JOUR AU - Szegedi, Andrea AU - Komlósi, Zsolt AU - Kapitány, Anikó AU - Csörgő Sándorné Bata, Zsuzsanna AU - Koncz, Gábor AU - Bácsi, Attila TI - The Complex Nomenclature of Allergic Diseases and Hypersensitivity Reactions: an Addendum to the EAACI Position Paper JF - ALLERGY: EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY J2 - ALLERGY VL - 80 PY - 2025 IS - 4 SP - 1162 EP - 1165 PG - 4 SN - 0105-4538 DO - 10.1111/all.16486 UR - https://m2.mtmt.hu/api/publication/35741354 ID - 35741354 N1 - Besorolása rövid közlemény a központi MTMT adminisztrátorokkal történt egyeztetés és az MTA V. Osztályának képviselője által végzett tartalmi vizsgálat alapján. (BCS, SZTE admin4, 2025-09-10) LA - English DB - MTMT ER - TY - JOUR AU - Charles-Schoeman, Christina AU - Schessl, Joachim AU - Csörgő Sándorné Bata, Zsuzsanna AU - Dimachkie, Mazen M AU - Griger, Zoltán AU - Moiseev, Sergey AU - Oddis, Chester V AU - Schiopu, Elena AU - Vencovsky, Jiri AU - Clodi, Elisabeth AU - Levine, Todd AU - Aggarwal, Rohit TI - Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study JF - RHEUMATOLOGY (UNITED KINGDOM) J2 - RHEUMATOLOGY VL - 64 PY - 2025 IS - 6 SP - 3767 EP - 3776 PG - 10 SN - 1462-0324 DO - 10.1093/rheumatology/keaf070 UR - https://m2.mtmt.hu/api/publication/35783046 ID - 35783046 AB - OBJECTIVES: The phase 3 ProDERM study demonstrated intravenous immunoglobulin (IVIg) was safe and effective in patients with dermatomyositis (DM). This analysis assessed clinical and serological predictors of IVIg response in DM patients from ProDERM.; METHODS: ProDERM was a prospective, randomised, placebo-controlled study of DM patients. For Weeks 0-16, patients received 2.0g/kg IVIg (Octagam, 10%) or placebo every 4weeks. Eligible patients entered the open-label extension phase, where all received IVIg to week 40. Univariate and multivariate analyses examined associations between baseline variables and total improvement score (TIS), including myositis disease activity assessment tool (MDAAT; assessing different organ involvement), and myositis-specific and myositis-associated autoantibodies.; RESULTS: Ninety-five patients were enrolled. Univariate analyses found no significant association between TIS at week 16 or 40 and age; sex; ethnicity; disease duration/activity; cutaneous, skeletal, gastrointestinal or muscle disease activity; or previous failed or concomitant medications.Multivariate analysis found patients with higher MDAAT cutaneous scores had a better chance of at least minimal TIS improvement. Higher MDAAT pulmonary scores were associated with a lower, but still considerable, chance of improvement. Patients with TIF1-gamma antibodies had a better TIS response; however, after controlling for cutaneous disease activity, there was no significant association between antibody classification (including anti-TIF1-gamma) and efficacy outcome.; CONCLUSION: IVIg was effective in treating DM patients regardless of demographic features and autoantibody status (for most autoantibodies). Patients with higher cutaneous disease activity and/or anti-TIF1-gamma responded best to IVIg, while pulmonary disease activity predicted a lower, but still effective, IVIg response, warranting further investigation.; CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02728752. © The Author(s) 2025. Published by Oxford University Press on behalf of the British Society for Rheumatology. LA - English DB - MTMT ER - TY - CONF AU - Bozó, Renáta AU - Virág, Nikolett AU - Flink, Lili Borbála AU - Hunyadi-Gulyás, Éva AU - Darula, Zsuzsanna AU - Gyulai, Rolland Péter AU - Kemény, Lajos AU - Csörgő Sándorné Bata, Zsuzsanna TI - The proteome of keratinocyte cultures from different types of nonlesional psoriatic skin exhibits distinct characteristics T2 - 10th ÖGDV SCIENCE DAYS PB - ÖGDV Austrian Society Of Dermatology And Venereology C1 - Werfenweng PY - 2025 SP - 23 EP - 23 PG - 1 UR - https://m2.mtmt.hu/api/publication/36055964 ID - 36055964 N1 - HCEMM-USZ Skin Research Group, Szeged, Hungary LA - English DB - MTMT ER - TY - JOUR AU - Gwathmey, Kelly G AU - Broome, Catherine M AU - Goebeler, Matthias AU - Murai, Hiroyuki AU - Csörgő Sándorné Bata, Zsuzsanna AU - Newland, Adrian C AU - Allen, Jeffrey A AU - Miyakawa, Yoshitaka AU - Ulrichts, Peter AU - Truyen, Luc AU - Podhorna, Jana AU - Kerstens, Rene AU - Steeland, Sophie AU - Beauchamp, Jon AU - Guptill, Jeffrey T AU - Howard, James F Jr TI - Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases JF - EXPERT REVIEW OF CLINICAL IMMUNOLOGY J2 - EXPERT REV CLIN IMMUNOL VL - 21 PY - 2025 IS - 5 SP - 627 EP - 638 PG - 12 SN - 1744-666X DO - 10.1080/1744666X.2025.2497840 UR - https://m2.mtmt.hu/api/publication/36118660 ID - 36118660 AB - BACKGROUND: Efgartigimod is approved in multiple regions for the treatment of gMG, ITP, and CIDP, and is being evaluated in multiple IgG-mediated autoimmune diseases. Here, we report the long-term safety profiles of efgartigimod IV and PH20 SC across different dosing regimens and diseases where efgartigimod has received regulatory approval.; RESEARCH DESIGN AND METHODS: Efgartigimod safety was assessed across dosing regimens and administration routes in Phase 2, placebo-controlled Phase 3, and OLE studies in participants with gMG, ITP, and CIDP. Analyses were performed on all participants who received≥1 dose or partial dose of efgartigimod or placebo. Data from efgartigimod-treated participants were pooled per disease. Event rates were calculated as events per PYFU.; RESULTS: Pooled data included 715 participants representing>850 PYFU. In efgartigimod-treated participants, most TEAEs were mild-to-moderate in severity, with consistently low event rates for TEAE-related treatment discontinuation (range: 0.05-0.47). Severe and serious infection rates were comparable between placebo- and efgartigimod-treated participants. Rates of TEAEs, severe and serious infections, and treatment discontinuation did not increase with prolonged efgartigimod exposure. Efgartigimod did not reduce albumin or increase LDL cholesterol levels.; CONCLUSIONS: Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen. LA - English DB - MTMT ER - TY - JOUR AU - Szadai, Leticia AU - Belső, Nóra AU - Ladóczky-Hulló, Daniella AU - Varga, Erika AU - Korom, Irma AU - Csörgő Sándorné Bata, Zsuzsanna TI - Beneficial Therapeutic Effect of Endothelin‐Receptor Antagonist in Generalized Morphea: A Report of Two Cases JF - INTERNATIONAL JOURNAL OF DERMATOLOGY J2 - INT J DERMATOL VL - 64 PY - 2025 IS - 12 SP - 2335 EP - 2337 PG - 3 SN - 0011-9059 DO - 10.1111/ijd.17900 UR - https://m2.mtmt.hu/api/publication/36204130 ID - 36204130 LA - English DB - MTMT ER - TY - JOUR AU - Aggarwal, Rohit AU - Schessl, Joachim AU - Csörgő Sándorné Bata, Zsuzsanna AU - Dimachkie, Mazen M. AU - Griger, Zoltán AU - Moiseev, Sergey AU - Oddis, Chester V. AU - Schiopu, Elena AU - Vencovsky, Jiri AU - Clodi, Elisabeth AU - Levine, Todd AU - Charles-Schoeman, Christina TI - Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study JF - RHEUMATOLOGY AND THERAPY J2 - RHEUMATOL THER VL - 12 PY - 2025 IS - 5 SP - 855 EP - 871 PG - 17 SN - 2198-6576 DO - 10.1007/s40744-025-00775-5 UR - https://m2.mtmt.hu/api/publication/36245474 ID - 36245474 N1 - Funding Agency and Grant Number: Octapharma Funding text: The authors thank the participants of the study. AB - Introduction: Muscle and skin involvement are well defined in dermatomyositis but other symptoms contribute significantly to the disease burden and their treatment is not well characterized. This post hoc analysis of ProDERM assessed the effect of intravenous immunoglobulin (IVIg) treatment on other manifestations of dermatomyositis beyond muscular and cutaneous involvement. Methods: ProDERM was a randomized, placebo-controlled study. For weeks 0-16, patients with dermatomyositis received 2.0 g/kg IVIg (Octagam, 10%) or placebo every 4 weeks. Eligible patients entered the open-label extension, where all received IVIg to week 40. Pulmonary, skeletal, constitutional, gastrointestinal, and cardiovascular disease activity was assessed using the myositis disease activity assessment tool, comprising a visual analog scale (VAS; 0-10 cm) and myositis intention-to-treat activity index. Results: Of 95 patients enrolled, 47 received IVIg and 48 received placebo to week 16. At baseline, 37.9% of patients experienced pulmonary, 64.2% experienced skeletal, 76.8% experienced constitutional, 33.7% experienced gastrointestinal, and 15.8% experienced cardiovascular involvement (VAS > 0.5). Among these patients, for those on IVIg, the following mean VAS scores decreased from baseline to week 16: pulmonary (37.7%; P = 0.001), skeletal (52.6%; P < 0.001), constitutional (44.4%; P < 0.001), and gastrointestinal (49.2%; P = 0.005). No corresponding improvement was seen with placebo except for constitutional VAS. With IVIg, the proportions of patients with arthritis (36.2 to 17.8%; P = 0.01), arthralgia (68.1 to 0.0%; P < 0.001), and fatigue (68.1 to 3.3%; P = 0.008) decreased from baseline to week 16. In the combined cohort, the proportions of patients with dysphonia (20.0 to 8.1%; P = 0.04), arthralgia (66.3 to 39.8%; P < 0.001), weight loss (10.5 to 3.4%; P = 0.04), fatigue (75.8 to 50.0%; P < 0.001), and dysphagia (40.0 to 18.4%; P < 0.001) decreased from baseline to week 40. Conclusion: IVIg was effective in treating pulmonary, skeletal, constitutional, and gastrointestinal manifestations of dermatomyositis. We advocate exploring IVIg as treatment for dermatomyositis, beyond muscle and skin manifestations. LA - English DB - MTMT ER - TY - JOUR AU - Flink, Lili Borbála AU - Ghaffarinia, Ameneh AU - Bozó, Renáta AU - Szűcs, Diána AU - Póliska, Szilárd AU - Balogh, Fanni AU - Degovics, Döníz AU - Veréb, Zoltán AU - Gyulai, Rolland Péter AU - Kemény, Lajos AU - Csörgő Sándorné Bata, Zsuzsanna TI - Psoriatic fibroblasts exhibit a distinct transcriptomic profile JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 17 PY - 2025 IS - 3 SP - 11 EP - 11 PG - 1 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/36858088 ID - 36858088 N1 - HCEMM-USZ Skin Research Group, Szeged, Hungary LA - English DB - MTMT ER - TY - JOUR AU - Bozó, Renáta AU - Virág, Nikolett AU - Flink, Lili Borbála AU - Hunyadi-Gulyás, Éva AU - Darula, Zsuzsanna AU - Ayaydin, Ferhan AU - Farkas, Attila AU - Gyulai, Rolland Péter AU - Kemény, Lajos AU - Csörgő Sándorné Bata, Zsuzsanna TI - Proteomic analysis reveals immune-related alterations in keratinocytes from non-lesional and resolved psoriatc skin JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 17 PY - 2025 IS - 3 SP - 24 EP - 24 PG - 1 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/36858165 ID - 36858165 N1 - HCEMM-USZ Skin Research Group, Szeged, Hungary LA - English DB - MTMT ER - TY - JOUR AU - Tassi, Nelli AU - Ghaffarinia, Ameneh AU - Nagy, Géza Róbert AU - Gyulai, Rolland Péter AU - Csörgő Sándorné Bata, Zsuzsanna AU - Kemény, Lajos AU - Bozó, Renáta TI - Inflammatory memory of psoriatic resolved keratinocytes JF - IMMUNOLÓGIAI SZEMLE J2 - IMMUNOLÓGIAI SZEMLE VL - 17 PY - 2025 IS - 3 SP - 45 EP - 45 PG - 1 SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/36858531 ID - 36858531 N1 - HCEMM-USZ Skin Research Group, Szeged, Hungary LA - English DB - MTMT ER - TY - JOUR AU - Tassi, Nelli AU - Ghaffarinia, Ameneh AU - Nagy, Géza Róbert AU - Gyulai, Rolland Péter AU - Csörgő Sándorné Bata, Zsuzsanna AU - Kemény, Lajos AU - Bozó, Renáta TI - Inflammatory memory of psoriatic resolved keratinocytes JF - BŐRGYÓGYÁSZATI ÉS VENEROLÓGIAI SZEMLE J2 - BVSZ VL - 101 PY - 2025 IS - 6 SP - 291 EP - 292 PG - 2 SN - 0006-7768 UR - https://m2.mtmt.hu/api/publication/36859195 ID - 36859195 N1 - HCEMM-USZ Skin Research Group, Szeged, Hungary LA - English DB - MTMT ER -